USD10
CRDF Shares
About Cardiff OncologyCardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
USD10
CRDF Shares
About Cardiff OncologyCardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Stats
TRADING WINDOW
Closed
OPENS AT
Sep 1 at 1:30 PM GMT+0
MARKET CAP
$77.8M
OPEN PRICE
Not enough data
LOW (1Y)
$0.7566
HIGH (1Y)
$3.31
LOW (24H)
$0.9026
HIGH (24H)
$1.01
VOLUME (24H)
$435.37K
171,981.03%
Price history
Time | Price | Change |
|---|---|---|
Today | Not enough data | Not enough data |
1 Day | $0.9301 | |
1 Week | $1.00 | 0.00% |
1 Month | $0.8554 | |
1 Year | $1.95 |
Past performance is not a reliable indicator of future results.
Discover more
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.